Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13990693 | 0.92 | PARP1 (0.51) | PARP1SLC11A2PTGER1PTGER4PTGER3 | |
| SCHEMBL30320123 | 0.91 | PARP1 (0.46) | PARP1SLC11A2PTGER1PTGER4PTGER3 | |
| SCHEMBL198085 | 0.91 | PARP1 (0.46) | PARP1SLC11A2PTGER1PTGER4PTGER3 | |
| SCHEMBL7877902 | 0.84 | GLA (0.56) | SLC11A2GLASTING1ALOX5AKR1B1 | |
| SCHEMBL3798516 | 0.81 | ALOX5 (0.57) | PARP1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL26977479 | 0.81 | F13A1 (0.47) | PARP1SLC11A2GLASTING1MAPT | |
| SCHEMBL26977641 | 0.79 | F13A1 (0.50) | GLASTING1MAPT | |
| SCHEMBL14252816 | 0.79 | CYP4F2 (0.57) | PARP1GLASTING1ALDH1A1HSD17B10 | |
| SCHEMBL3860960 | 0.79 | ALOX5 (0.42) | PARP1SLC11A2PTGER1PTGER4PTGER3 | |
| SCHEMBL3860950 | 0.77 | CYP1A2 (0.45) | PARP1PTGER1PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844070-B1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| JP-2008527017-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1844070-A1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| WO-2006077035-A9 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2006-10-26 | — | — | WO | claimed |
| WO-2006077035-A1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | claimed |
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | DANHO WALEED | 2006-07-20 | — | — | US | claimed |
| EP-1844070-B1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7410949-B2 | Genetically engineered truncated analogs of significantly lower-molecular-weight and having equal or better potency, pharmacokinetic properties and pharmacological properties as existing Y2R agonists; also pegylated analogs; treating obesity; dietetics; metabolic disorders | HOFFMANN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1844070-A1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006077035-A9 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006077035-A1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | DANHO WALEED | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160742-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | NPY2R, NPY1R, NPY4R | PARP1 3876/4885SLC11A2 1075/4885PTGER1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.